ClinicalTrials.gg
CompletedNCT05608343Updated Aug 15, 2024

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

A Phase 3 interventional study of Difamilast and Placebo in Atopic Dermatitis, sponsored by Acrotech Biopharma Inc.. Completed at 39 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
10th of 16
153 · median 177
Started
2022
with 2 others
Phase 3
10 of 16
2 open now
Registered
12th of 16
by date
Lead sponsor
2 of 16
Acrotech Biopharma Inc.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 10th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Important Inclusion Criteria:

  1. Subjects who are male or female ≥2 years of age
  2. Subjects and/or their parent(s)/legal guardian(s) (if subject is under the legal age of consent) provide written in accordance with federal and/or local laws prior to the conduct of any study-related procedures.
  3. Subjects who have a diagnosis of AD based on the American Academy of Dermatology AD diagnostic criteria
  4. Subjects who have had a diagnosis of AD for at least 6 months prior to Screening visit
  5. Subjects who have AD involvement ≥5% to ≤40% of treatable Body Surface Area (BSA) excluding scalp
  6. Subjects who have an AD Severity of mild (2) or moderate (3) as measured by the IGA of AD Severity score at screening and baseline visit

Important Exclusion Criteria:

  1. Female subjects who are pregnant or breastfeeding or who plan to become pregnant during the study and through 90 days after the last dose of study drug
  2. Subjects who have evidence of spontaneous clearance of AD between screening and baseline visits
  3. Subjects who have a history of unstable AD as assessed by the Investigator. Unstable AD is defined as disease flares occurring within 4 weeks prior to baseline visit
  4. Subjects who have an active or acute skin infection (eg, herpes simplex, herpes zoster, and chicken pox) and/or clinically infected AD
  5. Subject with greater than mild depression and suicidal ideation prior to screening or between screening and baseline visits
  6. Subjects who have a known history of alcohol abuse or illicit drugs within 6 months prior to screening

Etc.,

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Active comparator
    Difamilast Ointment

    1% Difamilast Ointment

    Drug: Difamilast

  • Placebo comparator
    Vehicle Controlled

    Matching placebo

    Drug: Placebo

Interventions

  • Off-white ointment containing active ingredient, petrolatum and other ingredients

  • DrugPlacebo

    Matching Difamilast (Study drug) ointment without active ingradient

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of twice-daily topical application of Difamilast ointment 1% compared to vehicle control in subjects ≥2 years of age with mild to moderate AD

    The proportion of subjects achieving success on the the 5-point Investigator Global Assessment (IGA) of AD Severity score at Day 29, and the success is defined as as a score of Clear (0) or Almost clear (1), with at least a 2-grade improvement from Baseline on the 5-point IGA of AD Severity score at Day 29

    Time frame: Baseline, Day 29

Secondary outcomes

  1. To further characterize the efficacy of Difamilast ointment 1% compared to vehicle control in subjects with mild to moderate AD

    The proportion of subjects achieving an IGA of AD Severity score of Clear (0) or Almost clear (1) at Day 29; the proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 22; the proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 15 The proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 22 The proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 15

    Time frame: Baseline, Day 15, Day 22 and Day 29

07

Study locations

39 sites
  • AllerVie Health
    Birmingham, Alabama 35244, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • NEA Baptist Clinic-Dermatology
    Jonesboro, Arkansas 72405, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Shahram Jacobs, MD Inc.
    Sherman Oaks, California 91403, United States
  • Clinical Trials Research Institute
    Thousand Oaks, California 91320, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • TrueBlue Clinical Research
    Brandon, Florida 33511, United States
  • Accel Research - Edgewater Clinical Research Unit
    Edgewater, Florida 32132, United States
  • Tory Sullivan, MD PA
    North Miami Beach, Florida 33162, United States
  • Nona Pediatrics
    Orlando, Florida 32829, United States
  • Accel Research - Ormond Clinical Research Unit
    Ormond Beach, Florida 32174, United States
  • Olympian Clinical Research
    Saint Petersburg, Florida 33706, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • DS Research
    Clarksville, Indiana 47129, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • South Bend Clinic
    South Bend, Indiana 46617, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • DermAssociates, LLC
    Rockville, Maryland 20850, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Oakland Hills Dermatology, PC
    Auburn Hills, Michigan 48326, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • Optima Research
    Boardman, Ohio 44512, United States
  • Remington-Davis, Inc.
    Columbus, Ohio 43215, United States
  • Peak Research, LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • North Texas Center for Clinical Research
    Frisco, Texas 75034, United States
  • Center for Clinical Studies, Ltd, LLP
    Houston, Texas 77004, United States
  • Houston Center for Clinical Research
    Sugar Land, Texas 77479, United States
  • Premier Clinical Research, LLC
    Spokane, Washington 99202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2023, 12 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2022
First posted
Nov 8, 2022
StartActual
Oct 1, 2022
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Results delay requested
Aug 13, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05608343
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Oct 1, 2022
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Last update
Aug 15, 2024

Study contacts

Uma Srinivas Atmuri, MPharm MS
study director · Acrotech Biopharma Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion